One-compound-multiple-targets strategy to combat Alzheimer's disease

FEBS Letters

Volumn 579, Issue 24, 2005, Pages 5260-5264

  Zhang, Hong Yu ^a  

^a SHANDONG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Acetylcholinesterase; Amyloid aggregation; Metal ions; Monoamine oxidase; Multipotent agents; Reactive oxygen species

Indexed keywords

ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING); AMYLOID BETA PROTEIN; AP 2238; CAPROCTAMINE; CARBAMIC ACID DERIVATIVE; CATECHOL; CHOLINESTERASE INHIBITOR; CHROMONE DERIVATIVE; CLIOQUINOL; COUMARIN DERIVATIVE; CURCUMIN; EPICATECHIN 3 GALLATE; EPICATECHIN GALLATE; GOSSYPETIN; LIPOCRINE; METAL ION; MONOAMINE OXIDASE INHIBITOR; MYRICETIN; PHYSOSTIGMINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; TAU PROTEIN; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ALZHEIMER DISEASE; CURCUMA LONGA; DRUG ABSORPTION; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RISK ASSESSMENT; SAFETY; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL PRODUCTS; HUMANS;

CURCUMA LONGA;

EID: 25844505550     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2005.09.006     Document Type: Short Survey

References (39)

1. L.K. Buehler Advancing drug discovery-beyond design PharmaGenomics 4 2004 24 26
2. C.T. Keith, A.A. Borisy, and B.R. Stockwell Multicomponent therapeutics for networked systems Nat. Rev. Drug Discov. 4 2005 71 78
3. M.P. Mattson Pathways towards and away from Alzheimer's disease Nature 430 2004 631 639
4. J.L. Cummings Alzheimer's Disease N. Engl. J. Med. 351 2004 56 67
5. K.J. Barnham, C.L. Masters, and A.I. Bush Neurodegenerative diseases and oxidative stress Nat. Rev. Drug Discov. 3 2004 205 214
6. D.R. Brown, and H. Kozlowski Biological inorganic and bioinorganic chemistry of neurodegeneration based on prion and Alzheimer diseases Dalton Trans. 13 2004 1907 1917
7. M. Citron Strategies for disease modification in Alzheimer's disease Nat. Rev. Neurosci. 5 2004 677 685
8. D.M. Fink, M.G. Palermo, G.M. Bores, F.P. Huger, B.E. Kurys, M.C. Merriman, G.E. Olsen, W. Petko, and G.J. O'Malley Imino 1,2,3,4- tetrahydrocyclopent[b]indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase Bioorg. Med. Chem. Lett. 6 1996 625 630
9. C. Brühlmann, F. Ooms, P.-A. Carrupt, B. Testa, M. Catto, F. Leonetti, C. Altomare, and A. Carotti Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase J. Med. Chem. 44 2001 3195 3198
10. J. Sterling, Y. Herzig, T. Goren, N. Finkelstein, D. Lerner, W. Goldenberg, I. Miskolczi, S. Molnar, F. Rantal, T. Tamas, G. Toth, A. Zagyva, A. Zekany, G. Lavian, A. Gross, R. Friedman, M. Razin, W. Huang, B. Krais, M. Chorev, M.B. Youdim, and M. Weinstock Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 45 2002 5260 5279
11. G.V. De Ferrari, M.A. Canales, I. Shin, L.M. Weiner, I. Silman, and N.C. Inestrosa A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation Biochemistry 40 2001 10447 10457
12. L. Piazzi, A. Rampa, A. Bisi, S. Gobbi, F. Belluti, A. Cavalli, M. Bartolini, V. Andrisano, P. Valenti, and M. Recanatini 3-(4-[Benzyl(methyl) amino]methylphenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer's disease therapy J. Med. Chem. 46 2003 2279 2282
13. M. Rosini, V. Andrisano, M. Bartolini, M.L. Bolognesi, P. Hrelia, A. Minarini, A. Tarozzi, and C. Melchiorre Rational approach to discover multipotent anti-Alzheimer drugs J. Med. Chem. 48 2005 360 363
14. C. Melchiorre, V. Andrisano, M.L. Bolognesi, R. Budriesi, A. Cavalli, V. Cavrini, M. Rosini, V. Tumiatti, and M. Recanatini Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease J. Med. Chem. 41 1998 4186 4189
15. C.W. Ritchie, A.I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q.X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R.E. Tanzi, and C.L. Masters Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch. Neurol. 60 2003 1685 1691
16. H.-F. Ji, and H.-Y. Zhang A new strategy to combat Alzheimer's disease. Combining radical-scavenging potential with metal-protein-attenuating ability in one molecule Bioorg. Med. Chem. Lett. 15 2005 21 24
17. G.P. Lim, T. Chu, F. Yang, W. Beech, S.A. Frautschy, and G.M. Cole The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse J. Neurosci. 21 2001 8370 8377
18. V. Chandra, M. Ganguli, R. Pandav, J. Johnston, S. Belle, and S.T. DeKosky Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study Neurology 51 1998 1000 1008
19. S.A. Frautschy, W. Hu, P. Kim, S.A. Miller, T. Chu, M.E. Harris-White, and G.M. Cole Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology Neurobiol. Aging 22 2001 993 1005
20. P.S. Aisen Development of antiinflammatory therapy for Alzheimer's disease Drug Develop. Res. 56 2002 421 427
21. K. Ono, K. Hasegawa, H. Naiki, and M. Yamada Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro J. Neurosci. Res. 75 2004 742 750
22. F. Yang, G.P. Lim, A.N. Begum, O.J. Ubeda, M.R. Simmons, S.S. Ambegaokar, P.P. Chen, R. Kayed, C.G. Glabe, S.A. Frautschy, and G.M. Cole Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo J. Biol. Chem. 280 2005 5892 5901
23. L. Baum, and A. Ng Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models J. Alzheimer Dis. 6 2004 367 377
24. A. Barik, B. Mishra, L. Shen, H. Mohan, R.M. Kadam, S. Dutta, H.-Y. Zhang, and K.I. Priyadarsini Evaluation of new copper-curcumin complex as superoxide dismutase mimic and its free radical reactions Free Radic. Biol. Med. 39 2005 811 822
25. Shen, L., Zhang, H.-Y. and Ji, H.-F. (2005) A theoretical study on Cu(II)-chelating properties of curcumin and its implications for curcumin as a multipotent agent to combat Alzheimer's disease. J. Mol. Struct. (Theochem.), in press.
26. C.A. Rice-Evans, N.J. Miller, and G. Paganga Structure-antioxidant activity relationships of flavonoids and phenolic acids Free Radic. Biol. Med. 20 1996 933 956
27. S. Taniguchi, N. Suzuki, M. Masuda, S.-i. Hisanaga, T. Iwatsubo, M. Goedert, and M. Hasegawa Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins J. Biol. Chem. 280 2005 7614 7623
28. H.-Y. Zhang Structure-activity relationships and rational design strategies for radical-scavenging antioxidants Curr. Comput. Aided Drug Des. 1 2005 257 273
29. H.A. Lashuel, D.M. Hartley, D. Balakhaneh, A. Aggarwal, S. Teichberg, and D.J.E. Callaway New class of inhibitors of amyloid-β fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease J. Biol. Chem. 277 2002 42881 42890
30. V.C. Stephenson, R.A. Heyding, and D.F. Weaver The "promiscuous drug concept" with applications to Alzheimer's disease FEBS Lett. 579 2005 1338 1342
31. A. Chichirau, M. Flueraru, L.L. Chepelev, J.S. Wright, W.G. Willmore, T. Durst, H.H. Hussainc, and M. Charron Mechanism of cytotoxicity of catechols and a naphthalenediol in PC12-AC cells: the connection between extracellular autoxidation and molecular electronic structure Free Radic. Biol. Med. 38 2005 344 355
32. H.-F. Ji, G.-Y. Tang, and H.-Y. Zhang Theoretical elucidation on structure-activity relationships of antioxidant xanthones QSAR Combin. Sci. 24 2005 826 830
33. C. Brühlmann, A. Marston, K. Hostettmann, P.-A. Carrupt, and B. Testa Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors Chem. Biodivers. 1 2004 819 829
34. M.B. Nunez, F.P. Maguna, N.B. Okulik, and E.A. Castro QSAR modeling of the MAO inhibitory activity of xanthones derivatives Bioorg. Med. Chem. Lett. 14 2004 5611 5617
35. H.-F. Ji, G.-Y. Tang, and H.-Y. Zhang β-Lactam antibiotics are multipotent agents to combat neurological diseases Biochem. Biophys. Res. Commun. 333 2005 661 663
36. R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, and C.G. Glabe Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 300 2003 486 489
37. H. Zheng, S. Gal, L.M. Weiner, O. Bar-Am, A. Warshawsky, M. Fridkin, and M.B.H. Youdim Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition J. Neurochem. 95 2005 68 78
38. S. Gal, H. Zheng, M. Fridkin, and M.B.H. Youdim Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion J. Neurochem. 95 2005 79 88
39. M.B.H. Youdim, and J. Buccafusco Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders Trends Pharmacol. Sci. 26 2005 27 35